Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Prostate Cancer Therapeutics Market Forecast: Value Set To Climb From $13.95 Billion To $19.25 Billion
The prostate cancer therapeutics market size has demonstrated robust growth over recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. The historical increase in this market can be attributed to several factors, including a rise in prostate cancer incidence, an aging male demographic, innovations in oncology drugs, comprehensive hospital-based cancer care, and increased cancer screening efforts.
The prostate cancer therapeutics market size is anticipated to expand significantly in the coming years. Its valuation is projected to reach $19.25 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.4%. This projected growth can be attributed to factors such as the increasing adoption of precision oncology, the emergence of biomarker-driven therapies, the rise of oral oncology drugs, an expanding immunotherapy pipeline, and growing healthcare expenditure. Important trends for this forecast period encompass the increasing use of targeted therapies, greater utilization of PARP inhibitors, the broader application of immunotherapy in oncology, a shift towards oral cancer medications, and treatment selection guided by precision medicine.
Get A Free Sample Report With In-Depth Market Insights:
Prostate Cancer Therapeutics Market Growth Factors: What’s Supporting Expansion?
The prostate cancer therapeutics market is set to expand, driven by the increasing prevalence of prostate cancer. This disease, where malignant cells develop in the prostate gland, primarily affects older males, and its rising occurrence is linked to an aging demographic. The risk of developing prostate cancer significantly increases with age, and longer life expectancies mean more men are living long enough to be affected. Prostate cancer therapeutics aid in managing this condition by targeting cancer cells, slowing disease progression, and enhancing quality of life through various treatments like surgery, radiation, hormone therapy, and newer immunotherapies. For example, in January 2025, Prostate Cancer UK reported an increase in diagnosed cases from 50,751 in 2022 to 55,033 in 2023. Therefore, the growing incidence of prostate cancer is propelling the growth of the prostate cancer therapeutics market.
Prostate Cancer Therapeutics Market Segment Breakdown: Which Categories Lead On Revenue?
The prostate cancer therapeutics market covered in this report is segmented –
1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies
2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
5) By End User: Clinics, Hospitals, Other End Users
Subsegments:
1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors
2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens
3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy
5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound
Prostate Cancer Therapeutics Market Industry Trends: What’s Reshaping Demand?
Leading companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as a once-daily oral medication for advanced prostate cancer, to enhance patient adherence and improve overall treatment outcomes. This daily oral pill for advanced prostate cancer refers to therapies consumed each day to manage metastatic castration-resistant prostate cancer by inhibiting the effects of testosterone on cancer cells. For example, in January 2024, Zydus Lifesciences, an India-based firm, introduced Rexigo, India’s first oral once-a-day pill containing relugolix for patients with advanced prostate cancer. This convenient and affordable substitute for injectable hormone therapies quickly suppresses testosterone, assisting in controlling cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it removes the requirement for injectable treatments that necessitate administration by healthcare providers, thus providing greater convenience for patients. This launch signifies a substantial advancement in prostate cancer management in India, offering patients and doctors a new, convenient, safe, and cost-effective treatment alternative.
Prostate Cancer Therapeutics Market Leading Players And Competitive Positioning
Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.
View The Full Prostate Cancer Therapeutics Market Report:
Prostate Cancer Therapeutics Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









